Still buys VolitionRx (VNRX) shares and warrants for $24,518

Published 15/10/2025, 21:14
Still buys VolitionRx (VNRX) shares and warrants for $24,518

Director Timothy Still of Volitionrx LTD (NASDAQ:VNRX) acquired 48,076 shares of common stock at $0.51 per share, for a total value of $24,518. The purchase comes as the stock has fallen nearly 29% in the past week, with shares currently trading at $0.44. According to analyst targets ranging from $2 to $5, the stock appears significantly undervalued based on InvestingPro Fair Value analysis.

According to a Form 4 filing with the Securities and Exchange Commission, Still also purchased warrants to buy 48,076 shares of Volitionrx LTD. The warrants have an exercise price of $0.60 and expire on October 14, 2030. These warrants were purchased for $0.01 per warrant.

Following the transaction on October 14, 2025, Still directly owns 1,535,458 shares of Volitionrx LTD.

In other recent news, VolitionRx Limited announced the pricing of an underwritten public offering aimed at raising approximately $6 million before expenses. The company is offering 11,550,000 shares of common stock along with warrants, priced at $0.52 per share, with the warrants exercisable at $0.60 per share. The proceeds from this offering are intended to support research, product development, clinical studies, commercialization efforts, working capital, and potential strategic acquisitions. Newbridge Securities Corporation is managing the transaction, and they have a 30-day option to purchase up to an additional 15% of the shares and warrants offered.

In terms of analyst perspectives, H.C. Wainwright has reiterated a Buy rating on VolitionRx stock with a price target of $2.50. This comes after the company announced a co-marketing agreement with Hologic Diagenode, which could potentially lead to Hologic becoming an exclusive provider of Volition’s Nu.Q Discover service. Meanwhile, Benchmark has maintained its Hold rating on the stock without specifying a price target. These developments highlight the mixed analyst sentiment surrounding VolitionRx amid its strategic moves and financial activities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.